Produção Nacional
Revisado por pares
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
2020; Massachusetts Medical Society; Volume: 383; Issue: 12 Linguagem: Inglês
10.1056/nejmoa2001180
ISSN1533-4406
AutoresRichard Furie, Brad H. Rovin, Frédéric Houssiau, Ana Malvar, Y.K. Onno Teng, Gabriel Contreras, Zahir Amoura, Xueqing Yu, Chi-Chiu Mok, Mittermayer B. Santiago, Amit Saxena, Yulia Green, Beulah Ji, C. Kleoudis, Susan W. Burriss, Carly Barnett, David A. Roth,
Tópico(s)Liver Diseases and Immunity
ResumoIn adults with active lupus nephritis, the efficacy and safety of intravenous belimumab as compared with placebo, when added to standard therapy (mycophenolate mofetil or cyclophosphamide–azathioprine), are unknown.
Referência(s)